Could Ocugen Become the Next Moderna?

60
18
Favorite

Could Ocugen Become the Next Moderna?

Motley Fool2022-01-07

Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say "surprise" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（18）

huax
·2022-01-10
Ok
Reply
1
Report
PS153
·2022-01-08
great
Reply
2
Report
ddb
·2022-01-07
Great
Reply
4
Report
HOCK
·2022-01-07
With the amount of monopoly going on.. no delist very good liao
Reply
5
Report
Ahwei6868
·2022-01-07
Ok
Reply
4
Report
S土豪熊貓G
·2022-01-07
Long for it!
Reply
7
Report
CloudLoo
·2022-01-07
👍
Reply
3
Report
Hk01
·2022-01-07
Ok
Reply
2
Report
Bluem
·2022-01-07
Like
Reply
2
Report
edwinong
·2022-01-07
Lije
Reply
5
Report
whisky88
·2022-01-07
Doubt it[Facepalm]
Reply
6
Report
shwan
·2022-01-07
good
Reply
5
Report
Ignis
·2022-01-07
No
Reply
6
Report
hitithard
·2022-01-07
K
Reply
9
Report
Kazmir
·2022-01-07
Like
Reply
6
Report
AliPharma
·2022-01-07
ok
Reply
6
Report
Dennyeo
·2022-01-07
Yes no
Reply
5
Report
Jasonngui
·2022-01-07
Great
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2201121648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-07 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2201121648","market":"us","top_or_hot":-1,"title":"Could Ocugen Become the Next Moderna?","media":"Motley Fool","content":"<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","article_id":"2201121648","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","pubTimestamp":1641555582,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Ocugen faces a few major challenges.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","BK4532":"文艺复兴科技持仓","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓","BK4563":"昨日强势股","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BK4007":"制药","BK4568":"美国抗疫概念","OCGN":"Ocugen","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Ocugen会成为下一个现代吗？","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1,"OCGN":1,"PFE":0.63},"content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9006404529,"gmtCreate":1641808955262,"gmtModify":1676533649595,"author":{"id":"3587028325444709","authorId":"3587028325444709","name":"huax","avatar":"https://community-static.tradeup.com/news/bc321e35d2e38297403a43ba1b540b0f","vip":1,"hat":"https://static.tigerbbs.com/646756f1284a5a6480ed02cc4fa7d1d2","crmLevel":2,"crmLevelSwitch":1,"idStr":"3587028325444709","authorIdStr":"3587028325444709"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006404529","repostId":2201121648,"repostType":2,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006307817,"gmtCreate":1641602787574,"gmtModify":1676533633209,"author":{"id":"3564565270877568","authorId":"3564565270877568","name":"PS153","avatar":"https://static.tigerbbs.com/2e185e8aa9ee6ee618f951b9141b9e40","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3564565270877568","authorIdStr":"3564565270877568"},"htmlText":"great","listText":"great","text":"great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006307817","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006024471,"gmtCreate":1641560793996,"gmtModify":1676533629189,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006024471","repostId":2201121648,"repostType":2,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006024123,"gmtCreate":1641560646118,"gmtModify":1676533629181,"author":{"id":"3574326262963990","authorId":"3574326262963990","name":"HOCK","avatar":"https://static.tigerbbs.com/88799e7ae4e69750fd2f85687a24a9e3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574326262963990","authorIdStr":"3574326262963990"},"htmlText":"With the amount of monopoly going on.. no delist very good liao","listText":"With the amount of monopoly going on.. no delist very good liao","text":"With the amount of monopoly going on.. no delist very good liao","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006024123","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006025255,"gmtCreate":1641560516660,"gmtModify":1676533629220,"author":{"id":"3576210449115034","authorId":"3576210449115034","name":"Ahwei6868","avatar":"https://static.tigerbbs.com/1fd3c758c9658a33289fa552d6d0f3d2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3576210449115034","authorIdStr":"3576210449115034"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006025255","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006025318,"gmtCreate":1641560437080,"gmtModify":1676533629158,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578811676095048","authorIdStr":"3578811676095048"},"htmlText":"Long for it!","listText":"Long for it!","text":"Long for it!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006025318","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006067584,"gmtCreate":1641558287597,"gmtModify":1676533628975,"author":{"id":"3564392929863426","authorId":"3564392929863426","name":"CloudLoo","avatar":"https://community-static.tradeup.com/news/bc15f9c1f1323fbf492a8ec703aef854","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":5,"crmLevelSwitch":1,"idStr":"3564392929863426","authorIdStr":"3564392929863426"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006067584","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006067202,"gmtCreate":1641558276352,"gmtModify":1676533628968,"author":{"id":"4092737844653660","authorId":"4092737844653660","name":"Hk01","avatar":"https://static.tigerbbs.com/47f73b69bc4bb694a9b2dedd17efba98","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4092737844653660","authorIdStr":"4092737844653660"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006067202","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006065240,"gmtCreate":1641557515724,"gmtModify":1676533628823,"author":{"id":"3575980094521663","authorId":"3575980094521663","name":"Bluem","avatar":"https://static.tigerbbs.com/2ea0046117889d9c87b13a313a480e69","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":2,"crmLevelSwitch":0,"idStr":"3575980094521663","authorIdStr":"3575980094521663"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006065240","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006066630,"gmtCreate":1641556739241,"gmtModify":1676533628776,"author":{"id":"3581723087274150","authorId":"3581723087274150","name":"edwinong","avatar":"https://static.tigerbbs.com/d42f3dae28f8c1740e66011b66f51ccd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581723087274150","authorIdStr":"3581723087274150"},"htmlText":"Lije","listText":"Lije","text":"Lije","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006066630","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006068961,"gmtCreate":1641556364949,"gmtModify":1676533628745,"author":{"id":"4087640531027510","authorId":"4087640531027510","name":"whisky88","avatar":"https://static.tigerbbs.com/af71fe1af327fb30e5ba516ac180800d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087640531027510","authorIdStr":"4087640531027510"},"htmlText":"Doubt it[Facepalm]&nbsp;","listText":"Doubt it[Facepalm]&nbsp;","text":"Doubt it[Facepalm]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006068961","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006061587,"gmtCreate":1641556283470,"gmtModify":1676533628737,"author":{"id":"3561072096203079","authorId":"3561072096203079","name":"shwan","avatar":"https://static.tigerbbs.com/fb6398d4509a4b0dab2e079bf75c0660","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3561072096203079","authorIdStr":"3561072096203079"},"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006061587","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006061324,"gmtCreate":1641556160444,"gmtModify":1676533628729,"author":{"id":"3574686466924712","authorId":"3574686466924712","name":"Ignis","avatar":"https://static.tigerbbs.com/543d1f3e8b4901fba226eb61e5713bc4","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"3574686466924712","authorIdStr":"3574686466924712"},"htmlText":"No","listText":"No","text":"No","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006061324","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006061914,"gmtCreate":1641556114064,"gmtModify":1676533628729,"author":{"id":"3570063321997588","authorId":"3570063321997588","name":"hitithard","avatar":"https://static.tigerbbs.com/309ce7b357018aa7b946332c2fe8725c","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3570063321997588","authorIdStr":"3570063321997588"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006061914","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006061029,"gmtCreate":1641556088124,"gmtModify":1676533628721,"author":{"id":"3558609398993628","authorId":"3558609398993628","name":"Kazmir","avatar":"https://static.tigerbbs.com/6fbf34248b52f1c38a9dc30ae20b49d8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3558609398993628","authorIdStr":"3558609398993628"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006061029","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006063213,"gmtCreate":1641556000693,"gmtModify":1676533628714,"author":{"id":"3586596744781365","authorId":"3586596744781365","name":"AliPharma","avatar":"https://static.tigerbbs.com/4ae50feeb2edce44d991e8e753fb37e5","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3586596744781365","authorIdStr":"3586596744781365"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006063213","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006063803,"gmtCreate":1641555951096,"gmtModify":1676533628706,"author":{"id":"3582021832486442","authorId":"3582021832486442","name":"Dennyeo","avatar":"https://static.tigerbbs.com/25b7d84fd64f134409a4350c85c88965","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582021832486442","authorIdStr":"3582021832486442"},"htmlText":"Yes no","listText":"Yes no","text":"Yes no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006063803","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006063928,"gmtCreate":1641555840037,"gmtModify":1676533628706,"author":{"id":"3581937655679729","authorId":"3581937655679729","name":"Jasonngui","avatar":"https://static.tigerbbs.com/4257d49eb28e662a88192e8c09a3ffaf","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581937655679729","authorIdStr":"3581937655679729"},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006063928","repostId":2201121648,"repostType":4,"repost":{"id":"2201121648","kind":"highlight","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":60,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}